These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Weisberg E; Manley PW; Cowan-Jacob SW; Hochhaus A; Griffin JD Nat Rev Cancer; 2007 May; 7(5):345-56. PubMed ID: 17457302 [TBL] [Abstract][Full Text] [Related]
7. JAK2 inhibitors: not the next imatinib but researchers see other possibilities. Garber K J Natl Cancer Inst; 2009 Jul; 101(14):980-2. PubMed ID: 19584324 [No Abstract] [Full Text] [Related]
8. Establishment and characterization of a novel imatinib-sensitive chronic myeloid leukemia cell line MYL, and an imatinib-resistant subline MYL-R showing overexpression of Lyn. Ito T; Tanaka H; Kimura A Eur J Haematol; 2007 May; 78(5):417-31. PubMed ID: 17432977 [TBL] [Abstract][Full Text] [Related]
10. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation. Rahmani M; Nguyen TK; Dent P; Grant S Mol Pharmacol; 2007 Sep; 72(3):788-95. PubMed ID: 17595328 [TBL] [Abstract][Full Text] [Related]
11. [Imatinib--a new perspective in the treatment of tumors]. Klener P; Klamová H Cas Lek Cesk; 2004; 143(9):579-80, 582-3. PubMed ID: 15532894 [TBL] [Abstract][Full Text] [Related]
12. [Chronic myeloid leukemia--resistance to imatinib mesylate (Glivec)--literature review and personal experience]. Nausová J; Priwitzerová M; Jarosová M; Indrák K; Faber E; Divoký V Cas Lek Cesk; 2006; 145(5):377-82. PubMed ID: 16755775 [TBL] [Abstract][Full Text] [Related]
13. Imatinib mesylate, a selective inhibitor of BCR-ABL, in chronic myeloid leukemia. Carella AM Expert Rev Anticancer Ther; 2007 Mar; 7(3):249-51. PubMed ID: 17338645 [No Abstract] [Full Text] [Related]
14. Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders. Cortes J; Kantarjian H Cancer; 2004 May; 100(10):2064-78. PubMed ID: 15139047 [TBL] [Abstract][Full Text] [Related]